Ascendis Pharma (ASND) reported a Q1 diluted loss late Thursday of 1.58 euros ($1.78) per share, narrowing from a loss of 2.30 euros a year earlier.
Analysts polled by FactSet expected a loss of 1.47 euros.
Revenue for the quarter ended March 31 was 101 million euros, up from 95.9 million euros a year earlier.
Analysts surveyed by FactSet expected 94.9 million euros.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。